Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1Phase 1 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 4Lymphoid 2Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma 2Leukemia 2Infections 2Hematologic Neoplasms 2Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Immunoglobulins, Intravenous × Other hematologic neoplasm × Clear all
NCT04438382 2026-06-02

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Eastern Cooperative Oncology Group

Phase 2 Terminated
1 enrolled 1 chart
Other hematologic neoplasm

Hematologic Neoplasms

NCT07202052 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Monash University

Phase 2/3 Recruiting
900 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms, Plasma Cell

NCT07202065 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Monash University

Phase 2/3 Recruiting
900 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT04634435 2025-01-20

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Biohaven Pharmaceuticals, Inc.

Phase 1 Completed
7 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡